Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 54 citing articles:

Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH)
Xiaohan Xu, Kyle L. Poulsen, Lijuan Wu, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 202
Breakthroughs in therapies for NASH and remaining challenges
Vlad Ratziu, Sven Francque, Arun J. Sanyal
Journal of Hepatology (2022) Vol. 76, Iss. 6, pp. 1263-1278
Open Access | Times Cited: 104
An adipocentric perspective on the development and progression of non-alcoholic fatty liver disease
Eun Young Lee, Hannelie Korf, António Vidal-Puig
Journal of Hepatology (2023) Vol. 78, Iss. 5, pp. 1048-1062
Open Access | Times Cited: 100
Inter-organ crosstalk during development and progression of type 2 diabetes mellitus
Georgia Xourafa, Melis Korbmacher, Michael Roden
Nature Reviews Endocrinology (2023) Vol. 20, Iss. 1, pp. 27-49
Open Access | Times Cited: 91
Nuclear Receptors Linking Metabolism, Inflammation, and Fibrosis in Nonalcoholic Fatty Liver Disease
Tobias Puengel, Hanyang Liu, Adrien Guillot, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 5, pp. 2668-2668
Open Access | Times Cited: 74
Pegbelfermin in Patients With Nonalcoholic Steatohepatitis and Compensated Cirrhosis (FALCON 2): A Randomized Phase 2b Study
Manal F. Abdelmalek, Arun J. Sanyal, Atsushi Nakajima, et al.
Clinical Gastroenterology and Hepatology (2023) Vol. 22, Iss. 1, pp. 113-123.e9
Open Access | Times Cited: 53
Pegbelfermin in Patients With Nonalcoholic Steatohepatitis and Stage 3 Fibrosis (FALCON 1): A Randomized Phase 2b Study
Rohit Loomba, Arun J. Sanyal, Atsushi Nakajima, et al.
Clinical Gastroenterology and Hepatology (2023) Vol. 22, Iss. 1, pp. 102-112.e9
Open Access | Times Cited: 44
Steatotic Liver Disease: Pathophysiology and Emerging Pharmacotherapies
Michail Kokkorakis, Emir Muzurović, Špela Volčanšek, et al.
Pharmacological Reviews (2024) Vol. 76, Iss. 3, pp. 454-499
Open Access | Times Cited: 30
Metabolic Dysfunction–Associated Steatotic Liver Disease: From Pathogenesis to Current Therapeutic Options
Piero Portincasa, Mohamad Khalil, Laura Mahdi, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 11, pp. 5640-5640
Open Access | Times Cited: 19
Drug Advances in NAFLD: Individual and Combination Treatment Strategies of Natural Products and Small-Synthetic-Molecule Drugs
Xing Wan, Jingyuan Ma, He Bai, et al.
Biomolecules (2025) Vol. 15, Iss. 1, pp. 140-140
Open Access | Times Cited: 2
A randomized, double-blind, placebo-controlled phase IIa trial of efruxifermin for patients with compensated NASH cirrhosis
Stephen A. Harrison, Peter Ruane, B. Freilich, et al.
JHEP Reports (2022) Vol. 5, Iss. 1, pp. 100563-100563
Open Access | Times Cited: 54
Targeting FGF21 in cardiovascular and metabolic diseases: from mechanism to medicine
Huiling Tan, Yue Tong, Zhengfang Chen, et al.
International Journal of Biological Sciences (2022) Vol. 19, Iss. 1, pp. 66-88
Open Access | Times Cited: 49
Combined Therapy with a CCR2/CCR5 Antagonist and FGF21 Analogue Synergizes in Ameliorating Steatohepatitis and Fibrosis
Tobias Puengel, Sander Lefere, Jana Hundertmark, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 12, pp. 6696-6696
Open Access | Times Cited: 43
Fibroblast Growth Factor–Based Pharmacotherapies for the Treatment of Obesity-Related Metabolic Complications
Leigang Jin, Ranyao Yang, Leiluo Geng, et al.
The Annual Review of Pharmacology and Toxicology (2022) Vol. 63, Iss. 1, pp. 359-382
Open Access | Times Cited: 43
The potential function and clinical application of FGF21 in metabolic diseases
Zhiwei Chen, Lili Yang, Yang Liu, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 39
Effect of pegbelfermin on NASH and fibrosis-related biomarkers and correlation with histological response in the FALCON 1 trial
Elizabeth A. Brown, Anne Minnich, Arun J. Sanyal, et al.
JHEP Reports (2023) Vol. 5, Iss. 4, pp. 100661-100661
Open Access | Times Cited: 28
Biological and pharmacological functions of the FGF19- and FGF21-coreceptor beta klotho
Alexandra S. Aaldijk, Cristy R.C. Verzijl, Johan W. Jonker, et al.
Frontiers in Endocrinology (2023) Vol. 14
Open Access | Times Cited: 26
Exerkines and cardiometabolic benefits of exercise: from bench to clinic
Leigang Jin, Candela Díaz-Cañestro, Yu Wang, et al.
EMBO Molecular Medicine (2024) Vol. 16, Iss. 3, pp. 432-444
Open Access | Times Cited: 15
Oligonucleotide therapies for nonalcoholic steatohepatitis
Sixu Li, Feng Xiong, Songbo Zhang, et al.
Molecular Therapy — Nucleic Acids (2024) Vol. 35, Iss. 2, pp. 102184-102184
Open Access | Times Cited: 9
Development of antifibrotic therapy for stricturing Crohn’s disease: lessons from randomized trials in other fibrotic diseases
Sinan Lin, Ren Mao, Chenchen Qian, et al.
Physiological Reviews (2021) Vol. 102, Iss. 2, pp. 605-652
Open Access | Times Cited: 51
Comprehensive Review and Updates on Holistic Approach Towards Non-Alcoholic Fatty Liver Disease Management with Cardiovascular Disease
Nicholas Chew, Cheng Han Ng, Mark Muthiah, et al.
Current Atherosclerosis Reports (2022) Vol. 24, Iss. 7, pp. 515-532
Closed Access | Times Cited: 32
Hepatic fibrosis: Targeting peroxisome proliferator-activated receptor alpha from mechanism to medicines
Lijun Gong, Fang Wei, Frank J. Gonzalez, et al.
Hepatology (2023) Vol. 78, Iss. 5, pp. 1625-1653
Open Access | Times Cited: 17
Pharmacotherapeutic options for metabolic dysfunction-associated steatotic liver disease: where are we today?
Tobias Puengel, Frank Tacke
Expert Opinion on Pharmacotherapy (2024) Vol. 25, Iss. 9, pp. 1249-1263
Open Access | Times Cited: 7
Liver Fibrosis and MAFLD: From Molecular Aspects to Novel Pharmacological Strategies
Weiyi Qu, Tengfei Ma, Jingjing Cai, et al.
Frontiers in Medicine (2021) Vol. 8
Open Access | Times Cited: 40
Exercise Is Medicine for Nonalcoholic Fatty Liver Disease: Exploration of Putative Mechanisms
James Westley Heinle, Kara DiJoseph, Angelo Sabag, et al.
Nutrients (2023) Vol. 15, Iss. 11, pp. 2452-2452
Open Access | Times Cited: 14
Page 1 - Next Page

Scroll to top